However, some studies have shown elevated PD-L1 expression in rectal cancer after CRT using immunohistochemistry [15–17], suggesting that immune checkpoint inhibitors in combination with CRT might enhance the response rate in advanced rectal cancer. The gene discussed is CD274; the disease is rectal cancer.